Inclusion Criteria:

          -  Patients with high risk AML who have achieved their FIRST complete remission (CR) or
             complete remission with incomplete count recovery (CRi) within 12 months of enrollment
             and are not immediately candidates for allogeneic stem cell transplant.

          -  Patients in their FIRST CR or CRi may be eligible for enrollment only if they have a
             high risk feature, including, but not limited to: adverse karyotype, FLT3 mutation,
             history of antecedent hematologic disorder (AHD), presence of dysplasia in the bone
             marrow, therapy-related AML, history of requiring more than 1 cycle of intensive
             induction chemotherapy to achieve first remission, or presence of persistent minimal
             residual disease (detected by cytogenetics, molecular markers, or flow cytometry) at
             any point after initial induction cycle. Patients aged > or = 18 years with AML who
             have achieved a SECOND CR or CRi within 12 months of enrollment and are not
             immediately candidates for allogeneic stem cell transplant are also eligible.

          -  Patients should have received induction chemotherapy for AML and at least 1
             consolidation.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of < or = 3.

          -  Serum total bilirubin < or = to 1.5 x the upper limit of normal (ULN).

          -  Serum creatinine < or = to 2.5 x ULN.

          -  Absolute neutrophil count (ANC) > 0.5 x k/mcgL.

          -  Platelet count > or = 30 x k/mgcL.

          -  For females of childbearing age, they may participate if they: a) Have a negative
             serum or urine pregnancy test within 10 to 14 days of enrolling; b) Agree to either
             abstinence or 2 effective contraceptive methods throughout the treatment period and up
             to 30 days after discontinuing treatment.

          -  For male patients with a female partner of childbearing age, they may participate if
             they agree to either abstinence or 2 effective contraceptive methods throughout the
             treatment period and up to 30 days after discontinuing treatment.

          -  Ability to understand and sign informed consent.

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by FAB classification based
             on morphology, immunophenotype, molecular, or cytogenetics studies.

          -  Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also
             ineligible unless they are unable or unwilling to receive therapy with a tyrosine
             kinase inhibitor.

          -  Uncontrolled intercurrent illness including, but not limited to active uncontrolled
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients with active central nervous system (CNS) disease.

          -  Patients with documented hypersensitivity to any components of the study program.

          -  Females who are pregnant or lactating or intending to become pregnant during the
             study.

          -  Patients with history of extramedullary AML, except for CNS involvement that is
             currently controlled, will not be eligible for enrollment.

          -  Patient should be removed from current trial if they wish to participate and get
             treatment on another trial.